Skip to main content

Myelofibrosis (ASCO) Basic Listing

Updates in Myelofibrosis
From the ASCO Annual Meeting

Conference Coverage
06/02/2024

Amber Denham

Amber Denham
Among patients with myelofibrosis who have both thrombocytopenia and anemia, study findings show full-dose pacritinib demonstrates efficacy for spleen, symptom, and transfusion response.
Among patients with myelofibrosis who have both thrombocytopenia and anemia, study findings show full-dose pacritinib demonstrates efficacy for spleen, symptom, and transfusion response.
Among patients with...
06/02/2024
Oncology
Conference Coverage
05/31/2024

Amber Denham

Amber Denham
Long-term follow-up results from a phase 2 trial highlight the promising efficacy of azacitidine in combination with ruxolitinib for patients with myelofibrosis.
Long-term follow-up results from a phase 2 trial highlight the promising efficacy of azacitidine in combination with ruxolitinib for patients with myelofibrosis.
Long-term follow-up results from...
05/31/2024
Oncology
Conference Coverage
05/31/2024

Amber Denham

Amber Denham
Cytopenias and/or proliferation, over JAK2 allele burden, correlate with outcomes of patients with primary myelofibrosis and with myelofibrosis from essential thrombocythemia or polycythemia vera, according to data presented at the 2024...
Cytopenias and/or proliferation, over JAK2 allele burden, correlate with outcomes of patients with primary myelofibrosis and with myelofibrosis from essential thrombocythemia or polycythemia vera, according to data presented at the 2024...
Cytopenias and/or proliferation,...
05/31/2024
Oncology
Conference Coverage
05/30/2024

Amber Denham

Amber Denham
Pelabresib plus ruxolitinib significantly reduced splenomegaly and improved anemia and bone marrow fibrosis compared with placebo plus ruxolitinib among JAK-inhibitor-treatment-naïve patients with myelofibrosis, according to updated phase 3...
Pelabresib plus ruxolitinib significantly reduced splenomegaly and improved anemia and bone marrow fibrosis compared with placebo plus ruxolitinib among JAK-inhibitor-treatment-naïve patients with myelofibrosis, according to updated phase 3...
Pelabresib plus ruxolitinib...
05/30/2024
Oncology